MedCity News October 23, 2024
An Alto drug candidate for major depressive disorder failed to meet primary and secondary goals of a placebo-controlled Phase 2b test. The disappointing result could stymie plans for further tests of the small molecule in PTSD and bipolar depression.
Neuropsychiatric drug development is rife with clinical trial failures, but Alto Neuroscience aims to overcome these hurdles with a precision medicine approach that matches a patient to a drug. A clinical trial failure for an Alto depression drug is now casting doubt on this program and the technology that is the foundation for the biotech company’s approach.
The Phase 2b failure of the drug, ALTO-100, comes nearly nine months after Mountain View, California-based Alto raised more than $128 million in an...
Today's Sponsors
Today's Sponsor